About this trial
This study will evaluate the implementation of integrating Guardian spatial emanators into the existing AVENIR II azithromycin mass drug administration program in Niger. The objective is to assess whether Guardian can be feasibly, acceptably, and effectively delivered through the same community-based platform already used for door-to-door azithromycin distribution to children 1 to 59 months of age.
Selected health center catchment areas in high-malaria-transmission settings in Niger will be randomized to integrated delivery or non-integrated delivery. The study will measure implementation outcomes including reach, coverage, acceptability, fidelity to protocol, costs, and product placement over time, and will also assess malaria-related clinic visits among children under 5 years of age using routine health facility data
Eligibility criteria
Qualifiers
Centre de Santé Intégré (CSI) catchment area participating in the AVENIR II azithromycin mass drug administration program
Located in a high malaria transmission setting in the study area
Randomly selected from the eligible pool for participation
Household located within a selected CSI catchment area
Disqualifiers
CSI catchment area not participating in the AVENIR II azithromycin mass drug administration program
Household not located within a selected CSI catchment area
Refusal of verbal consent by the head of household
Refusal of verbal consent by the CSI chief for CSI-level participation
Trial design
Treatments tested in this trial
- Spatial Emanator
Treatment groups
Sponsors and collaborators
University of California, San Francisco
Lead sponsor
Centre de Recherche Médicale et Sanitaire
Collaborator
Bill and Melinda Gates Foundation
Collaborator
Le Programme National de Santé Oculaire
Collaborator
Centre de recherche et interventions en santé publique (CRISP)
Collaborator
Ministère de la Santé Publique du Niger
Collaborator
S.C. Johnson & Son, Inc.
Collaborator